

SALUGGIA, NOVEMBER 14, 2014

THE BOARD OF DIRECTORS OF DIASORIN S.P.A. APPROVES THE CONSOLIDATED RESULTS FOR THE THIRD QUARTER OF 2014: INCREASE IN REVENUES AND PROFIT, STRONG FREE CASH FLOW AND SOLID NET FINANCIAL POSITION

FINANCIAL HIGHLIGHTS

- **REVENUES: € 109.0 million** in Q3'14, up 4.5% at CER (+4.6% at current exchange rate) compared with Q3'13, with molecular business contribution equal to € 0.7 million.
This result confirms the strong performance of CLIA ex-Vitamin D sales (+16.0% at CER and at current exchange rate) in all clinical areas (*Infectious Diseases, Prenatal Screening panel, HIV and Hepatitis assays line*), as well as the upward trend in sales of products that have been recently brought to market (*Gastrointestinal Infections and new 1,25 Vitamin D assay line*).
In the **first nine months** of 2014, revenues amounted to **€ 325.8 million**, up 2.5% at CER¹, with molecular business contribution equal to € 2.3 million.
- **MARGINALITY: in Q3'14, EBITDA totaled € 40.0 million**, equal to 36.7% of revenues. Excluding from EBITDA the positive effect of the exchange rates (+€ 0.7 million) and the molecular business (-€ 1.3 million), EBITDA margin would be equal to 37.5%.
In the **first nine months** of 2014, EBITDA totaled **€ 118.1 million**, equal to 36.2% of revenues. Excluding from EBITDA the costs for non-recurring events (-€ 1.2 million), the negative impact of the Euro appreciation (-€ 1.3 million) and the molecular business (-€ 4.0 million²), EBITDA margin would be equal to 37.8%.
- **NET PROFIT: € 21.3 million** in Q3'14, up 6.5% compared with Q3'13 and **€ 61.3 million** in the **first nine months** of 2014, equal to 18.8% of the Group's revenues. The **tax rates**, equal to 33.9% in Q3'14 (35.0% in Q3'13) and 35.5% in the **first nine months** of 2014 (37.4% in the first nine months of 2013), were both positively impacted by the computation of the Group's taxable profit across the different geographical areas, as well as by the tax rate reduction in Italy.
- **NET FINANCIAL POSITION: +€ 143.9 million** at **September 30, 2014** (+€ 45.9 million compared with the balance at the end of December 2013), net of the payment of € 29.9 million in ordinary dividends.
- **FREE CASH FLOW: € 32.1 million** in Q3'14 and **€ 71.2 million** at **September 30, 2014**.
- **LIAISON/LIAISON XL INSTALLED BASE: steady expansion** (net placements equal to **+152 units** in Q3'14; +141 LIAISON XL and +11 LIAISON), totaling **5,713 LIAISON and LIAISON XL units** at **September 30, 2014**, out of which 1,521 LIAISON XL (27% of the overall installed base).

SIGNIFICANT EVENTS

- **Launch of new tests on LIAISON/LIAISON XL analyzers:**
- **Adenovirus³:** test for the qualitative detection of Adenovirus in stool samples, in addition to the 5 most important tests of the "stool testing" panel, already available on the market (C. Difficile toxins A&B, C. Difficile GDH, Helicobacter Pylori, EHEC, Rotavirus).
 - **LIAISON XL murex HIV Ab/Ag high throughput (HT)⁴:** new test for the "blood banks" line on LIAISON XL. This test is designed for Blood Banks of medium and large size and offers a high operating efficiency (171 tests per hour on LIAISON XL) while providing a high level of specificity.

¹ negative effect of the exchange rates: -€ 6.1 million (+0.6% at current exchange rate)

² not inclusive of € 0.5 million of restructuring costs, which are included in the non-recurring events

³ outside the US and UK

⁴ outside the US and Canada

TABLES OF RESULTS

<i>Amounts in millions of euros</i>	Q3		change	
	2014	2013	amount	%
Consolidated net revenues	109.0	104.2	+4.8	+4.6% ^(a)
EBITDA	40.0	38.6	+1.4	+3.6%
<i>EBITDA margin</i>	<i>36.7%</i> ^(b)	<i>37.1%</i> ^(c)	<i>-0.4%</i>	
EBIT	32.2	31.7	+0.4	+1.4%
<i>EBIT margin</i>	<i>29.5%</i>	<i>30.4%</i>	<i>-0.9%</i>	
Consolidated net profit	21.3	20.0	+1.3	+6.5%

^(a) at CER: +4.5%

^(b) at CER, net of molecular: 37.5%

^(c) at CER, net of molecular: 39.0%

<i>Amounts in millions of euros</i>	9M		change	
	2014	2013	amount	%
Consolidated net revenues	325.8	323.9	+1.9	+0.6% ^(d)
EBITDA	118.1	122.5	-4.4	-3.6%
<i>EBITDA margin</i>	<i>36.2%</i> ^(e)	<i>37.8%</i> ^(f)	<i>-1.6%</i>	
EBIT	95.5	101.3	-5.8	-5.7%
<i>EBIT margin</i>	<i>29.3%</i>	<i>31.3%</i>	<i>-1.9%</i>	
Consolidated net profit	61.3	61.1	+0.2	+0.4%

^(d) at CER: +2.5%

^(e) at CER, net of molecular: 37.8%

^(f) at CER, net of molecular: 39.8%

COMMENT ON RESULTS

The Board of Directors of DiaSorin S.p.A., meeting today in Saluggia under the chairmanship of Gustavo Denegri, examined and approved the consolidated financial results for Q3'14.

In the foreign exchange market, the Euro appreciated against almost all currencies used by the Group, with a significant impact on the results achieved in the first nine months of 2014. Q3'14 reported a slowdown in the Euro appreciation vis-à-vis the U.S. dollar and a depreciation against the Australian dollar and the Brazilian real.

		U.S. Dollar	Australian Dollar	Brazilian Real	South African Rand
Euro	Q3'14	+0.1%	-1.0%	-0.6%	+7.8%
	9M'14	+2.9%	+9.5%	+11.1%	+16.3%

Revenues

Revenues: € 109.0 million in Q3'14, up 4.5% at CER (+4.6% at current exchange rate) compared with Q3'13.

This quarterly result confirms the strong performance of CLIA sales, net of Vitamin D, in all clinical areas as well as the upward trend in sales of products that have been recently brought to market (*Gastrointestinal Infections panel and new 1,25 Vitamin D assay line*).

In Q3'14, the sales performance highlights the following factors:

- **CLIA tests, net of Vitamin D: +16.0% at CER (+16.0% at current exchange rate)**, as a result of the successful LIAISON XL analyzer installations and new tests launched onto the market, mainly in the following product lines: Hepatitis, Infectious Diseases, Prenatal Screening and Gastrointestinal Infections (*DiaSorin continues to be the company with the broadest specialty CLIA menu, with 24 out of 111 tests available on LIAISON and LIAISON XL analyzers*).
- **Vitamin D test (CLIA): -7.2% at CER (-6.9% at current exchange rate)**, including the price reduction granted to LabCorp.
- **Instruments and consumables: +2.3% at CER (+2.2% at current exchange rate)**.
- **ELISA and RIA tests:** physiological decline of the contribution provided by these dated technologies working on open systems, despite a positive quarter for the line of Murex tests (*+9.2% at CER, +9.6% at current exchange rate*) following the upward trend in the Asian markets.
- **Molecular business tests:** equal to € 0.7 million.

In the **first nine months of 2014, revenues** amounted to **€ 325.8 million**, up 2.5% at CER (+0.6% at current exchange rate) compared with September 30, 2013. The depreciation of some of the currencies used by the Group had a negative impact of € 6.1 million compared with the same period last year.



The sales trend for the first nine months of 2014 is provided below:

- **CLIA tests, net of Vitamin D: +17.4% at CER (+15.9% at current exchange rate)**.
- **Vitamin D test (CLIA): -8.3% at CER (-10.6% at current exchange rate)**.
- **Instruments and consumables: -5.8% at CER (-7.8% at current exchange rate)**, negative trend resulting from the unfavourable comparison with large orders of instruments that occurred in Brazil and Spain during the first half of 2013.
- **ELISA and RIA tests:** physiological decline of the contribution provided by these dated technologies working on open systems.
- **Molecular business tests:** equal to € 2.3 million.

Steady **expansion** of the **analyzers** installed base.

In **Q3'14**, **LIAISON XL** net placements were equal to +141⁵. **LIAISON** net placements amounted to +11 units, for a total of **152 new installations** in the period.

In the **first nine months** of **2014**, **LIAISON XL** and **LIAISON** net placements were equal to +446 and -5 units, respectively, for a **total of 5,713 units in the LIAISON/LIAISON XL analyzers overall installed base**.

	Total units at December 31, 2013	Net placements in Q3'14	Net placements in 9M'14	Total units at September 30, 2014
 <p>LIAISON⁵</p>	4,197	+11	-5	4,192
 <p>LIAISON^{XL}</p>	1,075	+141	+446	1,521
TOTAL	5,272	+152	+441	5,713

⁵ out of which 5 units in the validation phase at customers' facilities.

Revenues
by
geography

The tables below provide a breakdown of the consolidated revenues of the DiaSorin Group by geographic region.

Amounts in millions of euros	Q3		Change		
	2014	2013	Amount	%	
				@ current	@ constant
Europe and Africa	51.8	49.6	+2.2	+4.5%	+4.4%
North America	26.7	26.1	+0.7	+2.6%	+2.8%
Asia Pacific	19.4	16.5	+2.9	+17.4%	+17.6%
Central and South America	11.1	12.1	-0.9	-7.8%	-9.1%
Total	109.0	104.2	+4.8	+4.6%	+4.5%

Amounts in millions of euros	9M		Change		
	2014	2013	Amount	%	
				@ current	@ constant
Europe and Africa	163.5	155.7	+7.9	+5.0%	+5.1%
North America	76.3	80.3	-4.0	-5.0%	-2.2%
Asia Pacific	53.7	50.8	+2.9	+5.7%	+8.5%
Central and South America	32.3	37.2	-4.9	-13.1%	-6.9%
Total	325.8	323.9	+1.9	+0.6%	+2.5%

% of revenues contributed	Q3		9M	
	2014	2013	2014	2013
Europe and Africa	47.5%	47.6%	50.2%	48.1%
North America	24.5%	25.0%	23.4%	24.8%
Asia Pacific	17.8%	15.8%	16.5%	15.7%
Central and South America	10.2%	11.6%	9.9%	11.4%

Europe and Africa

In Q3'14, revenues totaled € 51.8 million, up 4.4% at CER (+4.5% at current exchange rate) compared with Q3'13, driven by the growth in CLIA sales, net of Vitamin D, in all geographical areas.

In the first nine months of 2014, revenues amounted to € 163.5 million, up 5.1% at CER (+5.0% at current exchange rate).

- **Italy:**
 - Q3'14: +6.8% (local market: -0.3%⁶); growth driven by the upward trend in CLIA tests, net of Vitamin D (+8.2%), as well as in Vitamin D test (+16.0%).
 - 9M'14: +5.4%.
- **Germany:**
 - Q3'14: +10.8% (local market: +2.7%⁵); performance driven by CLIA tests, net of Vitamin D (+14.7%), specifically by Gastrointestinal Infections tests and 1,25 Vitamin D.
 - 9M'14: +14.6%.
- **France:**
 - Q3'14: -5.8% (local market: +1.0%⁵); trend affected by the contraction in sales volumes of Vitamin D tests as a result of the recent healthcare reform which has cut the number of tests approved for reimbursement. The performance of the other CLIA tests, net of Vitamin D, was positive and reported a progressive improvement (+25.1%).
 - 9M'14: -8.1%; decline in Vitamin D sales, partly offset by the upward trend in CLIA sales, net of Vitamin D (+22.7%).
- **Distributors⁷:**
 - Q3'14: -13.1%; performance affected by important tenders that have been postponed to the last quarter of 2014.
 - 9M'14: +0.1%.

⁶ EDMA latest data available

⁷ sales in markets where the Group has not a direct presence

North America

In Q3'14, revenues totaled € 26.7 million, up 2.8% at CER (+2.6% at current exchange rate) compared with Q3'13 and with a sequential growth if compared to the last quarters.

In the first nine months of 2014, revenues amounted to € 76.3 million, down 2.2% at CER (-5.0% at current exchange rate).

This performance is the net result of the following factors:

- **CLIA, net of Vitamin D:**
 - Q3'14: +85.7% at CER (+84.7% at current exchange rate); revenues were significantly impacted by the agreement with LabCorp concerning Infectious Diseases and Prenatal screening tests.
 - 9M'14: +77.2% at CER (+72.3% at current exchange rate).
- **Vitamin D:**
 - Q3'14: -9.9% at CER (-9.9% at current exchange rate); trend entirely due to the reduction in sales prices, also as a result of the agreement with LabCorp, despite rising volumes (+5.0%).
 - 9M'14: -13.5% at CER (-15.9% at current exchange rate).

Asia Pacific

In Q3'14, revenues totaled € 19,4 million, up 17.6% at CER (+17.4% at current exchange rate).

In the first nine months of 2014, revenues amounted to € 53.7 million, up 8.5% at CER (+5.7% at current exchange rate).

- **China:**
 - Q3'14: +19.1% at CER (+17.9% at current exchange rate) following both CLIA tests performance (+6.4% at CER) and the line of Murex tests (+125.0% at CER). Steady growth of LIAISON XL installed base, with 30 placements in Q3'14, totaling 98 LIAISON XL units.
 - 9M'14: +10.0% at CER (+6.9% at current exchange rate) confirming revenue gains for CLIA tests (+15.0% at CER) and for the line of Murex tests (+11.5% at CER).
- **Australia**
 - Q3'14: +6.5% at CER (+8.2% at current exchange rate); strong CLIA sales, net of Vitamin D (+43.2% at CER), that more than offset the decline in Vitamin D sales (-16.3% at CER).
 - 9M'14: +3.3% at CER (-5.7% at current exchange rate).
- **Distributors:**
 - Q3'14: +21.6% at current exchange rate; as a result of CLIA and Murex tests sales following new and important tenders that began in this area.
 - 9M'14: +7.8% at current exchange rate

Central and South America

In Q3'14, revenues amounted to € 11.1 million, down 9.1% at CER (-7.8% at current exchange rate) compared with Q3'13.

In the first nine months of 2014, revenues totaled € 32.3 million, down 6.9% at CER (-13.1% at current exchange rate).

- **Brazil:**
 - Q3'14: -17.4% at CER (-15.6% at current exchange rate); sales slowdown in the area, also as a result of the change occurred in the distribution network of Murex tests.
 - 9M'14: -11.8% at CER (-20.6% at current exchange rate); trend affected both by the cancellation of important orders of instruments that occurred in H1'13 and by the change in the distribution network of Murex tests.
- **Mexico**
 - Q3'14: +16.9% at CER (+15.0% at current exchange rate); sales growth due to business development of blood banks.
 - 9M'14: +35.8% at CER (+27.7% at current exchange rate).

▪ **Distributors:**

- Q3'14: -2.7% *at current exchange rate*; slowdown in sales as a result of socio-political instability in Venezuela, which is a strategic country in this area.
- 9M'14: -12.9% *at current exchange rate*.

Revenues
by
technology

The tables that follow show the percentage of the Group's consolidated revenues contributed by each technology.

% of revenues contributed	Q3	
	2014	2013
CLIA tests	70.7%	69.4%
ELISA tests	14.7%	14.9%
RIA tests	2.3%	3.0%
Instruments sales and other revenues	11.7%	12.0%
Molecular	0.6%	0.7%

% of revenues contributed	9M	
	2014	2013
CLIA tests	70.7%	68.1%
ELISA tests	14.4%	15.3%
RIA tests	2.5%	3.1%
Instruments sales and other revenues	11.7%	12.7%
Molecular	0.7%	0.8%

- **CLIA tests:** higher percentage on total revenues in Q3'14 (+1.3 percentage points) and in the first nine months of 2014 (+2.6 percentage points), as a result of an increase in CLIA tests sales on LIAISON analyzers and a slowdown in the Vitamin D negative trend.
- **ELISA and RIA tests:** progressive and physiological decline of the contribution provided by these technologies both in Q3'14 (-0.2 and -0.7 percentage points, respectively) and in the first nine months of 2014 (-0.9 and -0.6 percentage points, respectively), because more dated and working on open systems.
- **Instruments sales and other revenues:** percentage on total revenues in Q3'14 in line with Q3'13 (-0.3 percentage points) and down in the first nine months of 2014 (-1.0 percentage points), following the drop in revenues generated from instruments sales and the unfavorable comparison with 2013.
- **Molecular:** unchanged percentage on total revenues in Q3'14 and in the first nine months of 2014 compared with Q3'13 and the first nine months of 2013.

Operating performance

The following provides the Group operating performance in:

- i) Q3'14
- ii) 9M'14

In Q3'14, the Group margins were impacted by the different geographical and product mix of sales, as well as by a higher impact of medical equipment depreciations, due to the large number of LIAISON XL placements.

The first nine months of 2014 were further impacted by the negative effect of the exchange rate and by Murex supply disruption in Brazil. The Group will complete this transition in the next months of 2014.

Gross Profit

Gross Profit:

- i) € 72.4 million; 66.4% of revenues.
- ii) € 218.3 million; 67.0% of revenues.

EBITDA

EBITDA:

- i) € 40.0 million; 36.7% of revenues. Excluding the operating expenses to support molecular business (-€ 1.3 million) and the positive effect of the exchange rate (+€ 0.7 million), EBITDA margin would be equal to 37.5%.
- ii) € 118.1 million; 36.2% of revenues. Net of extraordinary events occurred to restructure some Group's branches and subsidiaries (-€ 1.2 million), the molecular business (-€ 4.0 million⁸) and the negative impact of the Euro appreciation (-€ 1.3 million), EBITDA margin would be equal to 37.8%.

EBIT

EBIT:

- i) € 32.2 million; 29.5% of revenues.
- ii) € 95.5 million, 29.3% of revenues.

Financial performance

In Q3'14, net financial income totaled +€ 0.08 million (-€ 0.9 million in Q3'13). Cumulative net financial income at September 30, 2014 amounted to -€ 0.5 million (-€ 3.8 million in 9M'13), due to the following factors:

- the measurement at fair value of the Group's financial instruments:
 - i) -€ 0.7 million (+€ 0.3 million in Q3'13).
 - ii) -€ 0.8 million (-€ 0.1 million in 9M'13).
- translation effect:
 - i) +€ 1.1 million (-€ 0.4 million in Q3'13) related to the dividends distributed by the U.S. subsidiary and the Euro exchange rate of subsidiaries' financial balances that use currencies different from the Group's reporting currency.
 - ii) +€ 1.6 million (-€ 1.3 million in 9M'13) related to the dividends distributed by the U.S. and South African subsidiaries, the Euro exchange rate of the intercompany financing disbursed to the Australian subsidiary and the financial balances of subsidiaries that use currencies different from the Group's Parent company's reporting currency.
- fees on factoring transactions:
 - i) -€ 0.3 million (-€ 0.5 million in Q3'13)
 - ii) -€ 1.0 million (-€ 1.6 million in 9M'13).

Income taxes

In Q3'14, income taxes totaled € 10.9 million, equal to a 33.9% tax rate, down 110 basis points when compared to a 35.0% tax rate in Q3'13, as a result of the the computation of the Group's taxable profit across the different geographical areas, as well as by the tax rate reduction in Italy.

At September 30, 2014 income taxes totaled € 33.8 million equal to a 35.5% tax rate, down 190 basis points when compared to a 37.4% tax rate in the first nine months of 2013.

Net profit

In Q3'14, the net profit totaled € 21.3 million, up 6.5% compared with Q3'13, equal to 19.5% of revenues, and amounted to € 61.3 million in the first nine months of 2014 (18.8% of revenues).

⁸ not inclusive of € 0.5 million of restructuring costs, which are included in the non-recurring events

NFP

At **September 30, 2014** the **Net Financial Position** was positive by **€ 143.9 million**, following the payment of € 29.9 million in ordinary dividends, up by € 45.9 million compared with the balance at the end of December 2013 (+€ 98.0 million), due to the cash flow generated from operating activities.

FCF

In **Q3'14**, the **Free Cash Flow** of the Group was equal to **€ 32.1 million** (€ 28,5 million in Q3'13) and to **€ 71.2 million** in the **first nine months of 2014** (€ 65.4 million in the first nine months of 2013).

Business Outlook

In view of the Group's operating performance after September 30, 2014 and taking into account possible evolutions of the global macroeconomic scenario and the diagnostic sector in particular, management confirms the guidance for 2014:

- Revenues: growth between 3% and 5% at CER compared with 2013
- EBITDA: growth equal to ca. 3% at CER compared with 2013
- LIAISON/LIAISON XL installed base: ca. 500

Luigi De Angelis, the Officer Responsible for the preparation of corporate financial reports of DiaSorin S.p.A., in accordance with the second subsection of art. 154-bis, part IV, title III, second paragraph, section V-bis, of Legislative Decree February 24, 1998, no. 58, declares that, to the best of his knowledge, the financial information included in the present document corresponds to book of accounts and book-keeping entries of the Company.

For additional information, please contact:

Riccardo Fava

Investor Relations & Corporate Communication Director

Tel. +39.0161.487988

riccardo.fava@diasorin.it

Margherita Sacerdoti

Investor Relations Specialist

Tel. +39.0161.487526

margherita.sacerdoti@diasorin.it

CONSOLIDATED INCOME STATEMENT

(Amounts in thousands of euros)	Q3		Change	
	2014	2013	amount	%
Sales and service revenues	109,025	104,202	+4,823	+4.6%
Cost of sales	(36,601)	(33,519)	-3,082	+9.2%
Gross profit	72,424	70,683	+1,741	+2.5%
	66.4%	67.8%	-1.4%	
Sales and marketing expenses	(21,592)	(20,303)	-1,289	+6.3%
Research and development costs	(6,177)	(5,524)	-653	+11.8%
General and administrative expenses	(12,377)	(11,405)	-972	+8.5%
Total operating expenses	(40,146)	(37,232)	-2,914	+7.8%
	(36.8)%	(35.7)%	-1.1%	
Other operating income (expense)	(128)	(1,736)	+1,608	-92.6%
<i>non recurring amount</i>	-	-	-	-
EBIT	32,150	31,715	+435	+1.4%
	29.5%	30.4%	-0.9%	
Net financial income (expense)	81	(937)	+1,018	-108.6%
Profit before taxes	32,231	30,778	+1,453	+4.7%
Income taxes	(10,920)	(10,764)	-156	+1.4%
Net profit	21,311	20,014	+1,297	+6.5%
EBITDA ⁽¹⁾	40,018	38,628	+1,390	+3.6%
	36.7%	37.1%	-0.4%	

(Amounts in thousands of euros)	9M		Change	
	2014	2013	amount	%
Sales and service revenues	325,796	323,921	+1,875	+0.6%
Cost of sales	(107,461)	(101,347)	-6,114	+6.0%
Gross profit	218,335	222,574	-4,239	-1.9%
	67.0%	68.7%	-1.7%	
Sales and marketing expenses	(65,647)	(63,334)	-2,313	+3.7%
Research and development costs	(18,553)	(17,711)	-842	+4.8%
General and administrative expenses	(36,669)	(35,907)	-762	+2.1%
Total operating expenses	(120,869)	(116,952)	-3,917	+3.3%
	(37.1)%	(36.1)%	-1.0%	
Other operating income (expense)	(1,928)	(4,324)	+2,396	-55.4%
<i>non recurring amount</i>	(1,218)	-	-1,218	n.m.
EBIT	95,538	101,298	-5,760	-5.7%
	29.3%	31.3%	-1.9%	
Net financial income (expense)	(455)	(3,806)	+3,351	-88.0%
Profit before taxes	95,083	97,492	-2,409	-2.5%
Income taxes	(33,799)	(36,437)	+2,638	-7.2%
Net profit	61,284	61,055	+229	+0.4%
EBITDA ⁽¹⁾	118,095	122,501	-4,406	-3.6%
	36.2%	37.8%	-1.6%	

(1) The Company defines EBITDA as the “result from operations” before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group’s operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group’s operating performance. Because the composition of EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

Third quarter and nine months unaudited data

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

<i>(Amounts in thousands of euros)</i>				
	ASSETS	09/30/2014	12/31/2013	Change
Non-current assets				
Property, plant and equipment		70,622	66,258	+4,364
Goodwill		67,234	65,503	+1,731
Other intangibles		50,608	53,911	-3,303
Equity investments		667	498	+169
Deferred-tax assets		20,679	20,872	-193
Other non-current assets		3,347	1,860	+1,487
	Total non-current assets	213,157	208,902	+4,255
Current assets				
Inventories		96,100	86,439	+9,661
Trade receivables		108,370	117,442	-9,072
Other current assets		9,924	8,689	+1,235
Other financial assets		24,005	34	+23,971
Cash and cash equivalents		124,000	105,110	+18,890
	Total current assets	362,399	317,714	+44,685
	TOTAL ASSETS	575,556	526,616	+48,940
<i>(Amounts in thousands of euros)</i>				
	LIABILITIES AND SHAREHOLDERS' EQUITY	09/30/2014	12/31/2013	Change
Shareholders' equity				
Share capital		55,948	55,948	-
Additional paid-in capital		18,155	18,155	-
Statutory reserve		11,190	11,181	+9
Other reserves and retained earnings		357,207	290,523	+66,684
Treasury shares		(44,882)	(44,882)	-
Net profit for the period attributable to shareholders of the Parent Company		61,284	83,028	-21,744
	<i>Equity attributable to shareholders of the Parent Company</i>	458,902	413,953	+44,949
Other reserves and retained earnings attributable to minority interests		213	99	+114
Net profit for the period attributable to minority interests		-	83	-83
	<i>Equity attributable to minority interests</i>	213	182	+31
	Total shareholders' equity	459,115	414,135	+44,980
Non-current liabilities				
Long-term borrowings		209	423	-214
Provisions for employee severance indemnities and other employee benefits		27,025	26,199	+826
Deferred-tax liabilities		3,532	3,499	+33
Other non-current liabilities		5,369	4,727	+642
	Total non-current liabilities	36,135	34,848	+1,287
Current liabilities				
Trade payables		36,313	36,601	-288
Other current liabilities		27,484	26,303	+1,181
Liabilities to the shareholders for the dividend		-	-	-
Income taxes payable		12,630	7,977	+4,653
Current portion of long-term debt		3,146	6,752	-3,606
Other financial liabilities		733	-	+733
	Total current liabilities	80,306	77,633	+2,673
	Total liabilities	116,441	112,481	+3,960
	TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	575,556	526,616	+48,940

Data at September 30th, 2014 unaudited

CONSOLIDATED STATEMENT OF CASH FLOWS

(Amounts in thousands of euros)	Q3	
	2014	2013
Cash and cash equivalents at beginning of period	88,717	67,506
Net cash from operating activities	39,015	36,706
Cash used in investing activities	(6,786)	(8,720)
Cash used in financing activities	3,054	(3,131)
Acquisitions of subsidiaries and business operations	-	-
Change in net cash and cash equivalents before investments in financial assets	35,283	24,855
Investments in financial assets	-	-
Change in net cash and cash equivalents	35,283	24,855
Cash and cash equivalents at end of period	124,000	92,361

(Amounts in thousands of euros)	9M	
	2014	2013
Cash and cash equivalents at beginning of period	105,110	104,599
Net cash from operating activities	91,885	85,450
Cash used in investing activities	(21,017)	(21,616)
Cash used in financing activities	(30,220)	(76,342)
Acquisitions of subsidiaries and business operations	-	270
Change in net cash and cash equivalents before investments in financial assets	40,648	(12,238)
Investments in financial assets	(21,758)	-
Change in net cash and cash equivalents	18,890	(12,238)
Cash and cash equivalents at end of period	124,000	92,361

Third quarter and nine months unaudited data

Luigi De Angelis, the Officer Responsible for the preparation of corporate financial reports of DiaSorin S.p.A., in accordance with the second subsection of art. 154-bis, part IV, title III, second paragraph, section V-bis, of Legislative Decree February 24, 1998, no. 58, declares that, to the best of his knowledge, the financial information included in the present document corresponds to book of accounts and book-keeping entries of the Company.